UNI-BIO GROUP: Signed a strategic cooperation agreement with SDKX to expand the global market for BoguTai®
UNI-BIO GROUP has signed a strategic cooperation agreement with SDKX, authorizing SDKX to exclusively commercialize Bogu Tai® in six countries: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. Since its launch in March 2024, the drug has performed exceptionally well, with expected revenue growth of 248.9% year-on-year in the first half of 2025. This cooperation provides a significant opportunity for Bogu Tai® to enter the market, with anticipated revenue by the end of 2026, supporting the group's globalization expansion strategy
According to the Zhitong Finance APP, UNI-BIO GROUP (00690) announced that its wholly-owned subsidiary Beijing Bokan Jian Gene Technology Co., Ltd. (Beijing Bokan Jian) has signed a strategic cooperation agreement with Sinovac Biotech Ltd. (Sinovac) to grant Sinovac exclusive commercialization rights for the innovative osteoporosis treatment drug Bogu Tai® in six countries (cooperation areas): Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.
Bogu Tai® is a new generation osteoporosis treatment drug that promotes bone formation and increases bone density. As China's first approved pre-filled pen injection of teriparatide, Bogu Tai® uses ultra-fine injection needles and a precise delivery system to reduce patient discomfort and improve medication adherence, providing patients with a more convenient and comfortable treatment experience. The drug is suitable for postmenopausal women at high risk of fractures, significantly filling the unmet medical needs in this field.
It is reported that the cooperation area has over 10 million osteoporosis patients, with a market size of nearly $1.5 billion. This cooperation provides an important opportunity for Bogu Tai® to enter these markets with significant unmet needs. Since its launch in China in March 2024, Bogu Tai® has achieved remarkable success, with revenue growth of up to 248.9% year-on-year in the first half of 2025. This cooperation will continue this strong development momentum, with revenue expected to be realized as early as the end of 2026, and a competitive pricing strategy will allow Bogu Tai® to achieve higher profit margins.
Sinovac Biotech Ltd. (688136.SH) is a leading innovative multinational biopharmaceutical company that has established and operates six overseas subsidiaries and offices, having gained market access and achieved sales in dozens of countries and regions worldwide, including the EU, Brazil, the Philippines, and Indonesia.
The board believes that this cooperation is a key milestone in the group's globalization expansion strategy, which not only consolidates its position in the osteoporosis treatment market but also brings long-term value to shareholders
